The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer

Yan-Fang Gao†1,2,3, Rui-Qing Peng†1,2, Jiang Li1,2, Ya Ding1,2, Xing Zhang1,2, Xiao-Jun Wu1,4, Zhi-Zhong Pan1,4, De-Sen Wan1,4, Yi-Xin Zeng1,2 and Xiao-Shi Zhang*1,2

Address: 1State Key Laboratory of Oncology in South China, 651 Dongfeng R E, 510060, Guangzhou, PR China, 2Biotherapy Center, Cancer Center, Sun Yat-sen University, 651 Dongfeng R E, 510060, Guangzhou, PR China, 3Department of Medical Oncology, Weifang People’s Hospital, 151 Guangwen Street, Kuiwen District, 261040, Weifang, PR China and 4Department of Abdominal Oncology, Cancer Center, Sun Yat-sen University, 651 Dongfeng R E, 510060, Guangzhou, PR China

Email: Yan-Fang Gao - gyf814@tom.com; Rui-Qing Peng - gz13724083175@126.com; Jiang Li - leejiang@tom.com; Ya Ding - dingya@mail.sysu.edu.cn; Xing Zhang - xingzhang@hotmail.com; Xiao-Jun Wu - wuxun@mail.sysu.edu.cn; Zhi-Zhong Pan - panzhzh@mail.sysu.edu.cn; De-Sen Wan - wds-fk@yahoo.com.cn; Yi-Xin Zeng - zengyix@mail.sysu.edu.cn; Xiao-Shi Zhang* - xxs617@hotmail.com

* Corresponding author †Equal contributors

Abstract

Background: One of the putative mechanisms of tumor immune escape is based on the hypothesis that carcinomas actively create an immunosuppressed state via the expression of indoleamine 2,3-dioxygenase (IDO), both in the cancer cells and in the immune cells among the tumor-draining lymph nodes (TDLN). In an attempt to verify this hypothesis, the patterns of expression of IDO in the cancer cells and the immune cells among colon cancers were examined.

Methods: Seventy-one cases of pathologically-confirmed colon cancer tissues matched with adjacent non-cancerous tissues, lymph node metastases, and TDLN without metastases were collected at the Sun Yat-sen Cancer Center between January 2000 and December 2000. The expression of IDO and Bin1, an IDO regulator, was determined with an immunohistochemical assay. The association between IDO or Bin1 expression and TNM stages and the 5-year survival rate in colon cancer patients was analyzed.

Results: IDO and Bin1 were detected in the cytoplasm of cancer cells and normal epithelium. In primary colon cancer, the strong expression of IDO existed in 9/71 cases (12.7%), while the strong expression of Bin1 existed in 33/71 cases (46.5%). However, similar staining of IDO and Bin1 existed in the adjacent non-cancerous tissues. Among the 41 cases with primary colon tumor and lymph node metastases, decreased expression of IDO was documented in the lymph node metastases. Furthermore, among the TDLN without metastases, a higher density of IDO+ cells was documented in 21/60 cases (35%). Both univariate and multivariate analyses revealed that the density of IDO+ cells in TDLN was an independent prognostic factor. The patients with a higher density of IDO+ cells in TDLN had a lower 5-year survival rate (37.5%) than the cells with a lower density (73.1%).

Conclusion: This study demonstrated paradoxical patterns of expression of IDO in colon cancer. The high density IDO+ cells existed in TDLN and IDO was down-regulated in lymph nodes with metastases, implying that IDO in tumor and immune cells functions differently.

Published: 20 August 2009

Journal of Translational Medicine 2009, 7:71 doi:10.1186/1479-5876-7-71

Received: 30 March 2009

Accepted: 20 August 2009

This article is available from: http://www.translational-medicine.com/content/7/1/71

© 2009 Gao et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

Most dietary tryptophan enters the kynurenine pathway, leading to the biosynthesis of NAD or resulting in the complete oxidation of amino acids for energy production. Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) can both function as the initial rate-limiting enzymes in the kynurenine pathway. Since IDO is expressed in various tissues, while TDO is localized almost exclusively in the liver, IDO appears to play a much more significant role in the kynurenine pathway than TDO [1-3]. Under physiologic conditions, IDO is expressed modestly, but it is highly induced by bacterial and viral infections [4].

Several lines of evidence from an experimental mouse model showed that IDO had immunoregulatory potential. First, placental IDO plays a crucial role in maternal-tolerance of the fetus [5,6]. Second, the activity of IDO results in significant prolongation of graft survival of allografted pancreas islets [7,8]. Finally, T cell-mediated experimental asthma is inhibited by the up-regulation of pulmonary IDO [9]. With respect to tumors, one of the mechanisms concerning tumor immune escape might be IDO-dependent. Indeed, animal tumors expressing a higher level of IDO effectively escape from immune surveillance of the host by degrading local tryptophan, which in turn inhibits T cell responses [10,11]. Furthermore, IDO expression has been documented in multiple solid human tumors, such as brain, breast, lung, thyroid, liver, pancreas, colon, rectum, kidney, bladder, prostate, ovarian, cervix, endometrium, and skin tumors [10,12-21]. In addition, IDO is expressed in tumor-draining lymph nodes (TDLN). It is widely thought that either or both of these sites of IDO expression serve to inhibit immune responses to tumors, although the supporting evidence is insufficient [22-25].

Based on the immunoregulatory effect of IDO, the anti-IDO therapeutic approach has been under investigation. Preliminary results have revealed that inhibition of IDO could delay tumor progression in a combined setting [26-29]. However, one should bear in mind that IDO exhibits multiple activities. For example, the kynurenine pathway is essential for cell biosynthesis. The IFN-γ-induced IDO-dependent antimicrobial effect against Toxoplasma gondii, Chlamydia psittaci, and group B streptococcal infections is postulated to be secondary to the degradation of the essential amino acid, L-tryptophan [30]. Additionally, the role of IDO in the antitumor activity of human IFN-γ remains controversial [31-33]. Therefore, more attention should be paid to the effect of IDO inhibition [34-36]. To test whether IDO activity in cancer cells and TDLN participates synchronously in tumor progression, the current study analyzed the expression of IDO in cancer cells from primary tumor and lymph node metastases, in normal epithelium from adjacent non-cancerous tissues, and in immune cells from TDLN without tumor involvement in colon cancer. The results showed the paradoxical patterns of expression of IDO; specifically, both a higher density of IDO+cells in TDLN and down-regulation of IDO in metastatic cancer cells were associated with poor prognosis in colon cancers.

Methods

Materials

Seventy-one cases of pathologically-confirmed specimens were obtained from colon cancer patients who underwent radical resection between January 2000 and December 2000 in the Cancer Center of Sun Yat-Sen University, Guangzhou, China (Table 1). All of the patients were treated with 5-FU-based adjuvant chemotherapy postoperatively for 6 months. Patients were evaluated every 3 months during the 1st year, every 6 months in the 2nd year, and by telephone or mail communication once every year thereafter, for a total of 5 years. If recurrence or metastasis occurred, 5-FU-based chemotherapy was given according to the NCCN guideline. Overall survival was defined as the time from surgery to death; alternatively, censoring was done at the last known date the patient was alive.

Immunohistochemical assay and scoring systems

The expression of IDO in primary tumors matched with adjacent non-cancerous tissues, lymph node involvement, and TDLN without tumor metastases was determined with an immunohistochemical assay. The expression of Bin1 in primary tumors matched with adjacent non-cancerous tissues was also determined with an immunohistochemical assay. Briefly, formalin-fixed, paraffin-embedded archived tissues were cut into 4-μm sections. Then, the sections were dewaxed, rehydrated, blocked
with hydrogen peroxide, and antigen was retrieved in a microwave in 10 mM citrate buffer (pH 6.0) for 10 minutes and cooled to room temperature. After blocking with 1% rabbit (or sheep) serum, the sections were incubated with sheep polyclonal antibody against human IDO at a dilution of 1: 50 (Hycult Biotechnology, Uden, The Netherlands) or mouse monoclonal antibody against human Bin1 at a dilution of 1:100 (Millipore Corporation, MA, USA) overnight at 4°C, followed by biotinylated secondary antibody and streptavidin-biotinylated horseradish peroxidase complex. The sections were developed with diaminobenzidine tetrahydrochloride (DAB) and counterstained with hematoxylin. Negative controls were made with primary antibody replaced by PBS.

The following two scoring systems were used: 1) determination of the expression of IDO and Bin1 in cancer cells and normal epithelium; and 2) determination of the density of IDO+ immune cells in TDLN. Each section was scored independently by two pathologists. If inconsistency existed, a third pathologist served to achieve consensus. In tumor and normal epithelium, the expression of IDO and Bin1 was interpreted for immunoreactivity using the 0–4 semi-quantitative system of Gastl [37] for both the intensity of staining and the percentage of positive cells (labeling frequency percentage). The intensity of membrane staining was grouped into the following 4 categories: no staining/background of negative controls (score = 0), weak staining detectable above background (score = 1), moderate staining (score = 2), and intense staining (score = 3). The labeling frequency was scored as 0 (≤ 5%), 1 (5% to 25%), 2 (26% to 50%), 3 (51% to 75%), and 4 (≥ 76%). The product index was obtained by multiplying the intensity and percentage scores, as follows: (−), (+), (++), and (+++) indicated sum indexes of 0~2, 3~5, 6~8, and 9~12, respectively; (−) and (+) were defined as no or modest expression, and (+++) and (++++) were defined as strong expression.

For the density of IDO+cells in TDLN, another scoring system was used. Slides were examined under a low power (×40~100) microscope to identify the regions containing the highest percentage of IDO+cells (hot spot) in the lymph nodes. Five fields of hot spots within the lymph nodes were selected under a higher power (×200) microscope, and the average number IDO+cells in each field was calculated. The cases with ≤ 50 IDO+cells in each field were considered to have a low density of IDO+cells in the TDLN, whereas the cases with > 50 IDO+cells in each field were considered to have a high density of IDO+cells in the TDLN.

Statistical analysis
The levels of IDO and Bin1 between primary tumor and adjacent epithelium or the levels of IDO between primary tumors and matched lymph node metastases were analyzed with a chi-square test or Fisher's exact test. The correlation between IDO expression and Bin1 expression, or the correlation between IDO expression or Bin1 expression and TNM stages was analyzed with Spearman rank correlation. The following factors were assessed with both univariate and multivariate analyses to determine the influence on overall survival: T stage, N stage, M stage, IDO expression in the primary tumor, Bin1 expression in the primary tumor, and the density of IDO+ cells in TDLN without metastases. Kaplan-Meier curves were used to estimate the distributions of those variables to survival and compared with the log-rank test. The Cox regression model was used to correlate assigned variables with overall survival. All statistical analyses were carried out using SPSS 13.0 software (SPSS Inc., Chicago, IL, USA). Statistical significance was assumed for a two-tailed P < 0.05.

Results
The patterns of expression of IDO and Bin1
The expression of IDO was detected in the cytoplasm of tumor cells, normal epithelium, and immune cells. The staining of IDO occurred on both the luminal and basal surfaces of tumor cells and normal epithelial cells. In the same section, staining of IDO occurred both in cancer cells and normal epithelial cells (Fig. 1A, B). Similar staining of IDO also occurred in the tumor cells which had metastasized to the lymph nodes. As most of the sections lacked normal lymph tissue around the nests of cancer cells, the density of IDO+immune cells around the metastases was not available (Fig. 1C). The expression of IDO was detected on dendritic cell-like cells in the TDLN without metastases, which were derived from 27 patients without lymph node involvement (N0) and 33 patients with lymph node involvement (N1–3; Fig. 1D). According to the definition regarding the density of IDO+cells in TDLN (vide supra), 21 cases were grouped as high density IDO+ cells in TDLN and 39 cases as low density of IDO+ cells. Bin1 was also detected in the cytoplasm in the primary tumors and adjacent non-cancerous epithelium (Fig. 1E, F).

Comparison of the expression of IDO and Bin1 between primary tumors and lymph node metastases
Strong expression (++++++) of IDO was documented in 9 of the 71 patients, while strong expression of Bin1 was documented in 33 cases. Since IDO stained both on the primary tumor cells and the normal epithelial cells, the levels of IDO between primary tumors and matched adjacent epithelium was compared; no difference existed (Table 2). The intensity of IDO between primary tumors and lymph node involvement was compared among the 41 cases which have matched primary tumors and lymph node involvements, and showed that the expression of IDO in lymph node involvement decreased (Table 3). The
Figure 1
Expression of IDO and Bin1 in colon cancer. IDO is expressed in primary colon cancer cells (A), in adjacent non-cancerous epithelium (B) in lymph node metastases (C), and in tumor-draining lymph nodes without metastasis (D). Bin1 is also expressed in cancer cells and epithelium (E, F; immunohistochemical assay, ×200).
Table 2: The expression of IDO or Bin1 in primary tumors and matched adjacent non-cancerous epithelium (N = 71)

|                | IDO expression |       |       |       | P value |       |       |       |       | P value |
|----------------|---------------|-------|-------|-------|---------|-------|-------|-------|-------|---------|
|                | -             | +     | ++    | +++   |         | -     | +     | ++    | +++   |         |
| Primary tumor  | 40 (56.3)     | 22 (31.0) | 6 (8.5) | 3 (4.2) | 0.936   | 21 (29.6) | 17 (23.9) | 19 (26.8) | 14 (19.7) | 0.350   |
| Adjacent epithelium | 42 (59.2)   | 20 (28.1) | 7 (9.9) | 2 (2.8) |         | 12 (16.9) | 19 (26.8) | 22 (31.0) | 18 (25.3) |         |

Relationship between survival and TNM stages; the levels of IDO and Bin1 assessed with univariate survival analysis

By the end of the 5-year follow-up, 39 patients were still alive, thus the 5-year survival rate in this group of patients was 55%. Before univariate and multivariate analyses, the correlation between the level of IDO or Bin1 with the TNM stages was analyzed. Neither IDO nor Bin1 expression correlated with TNM stages (data not shown). Then, the TNM stages, and the levels of IDO and Bin1 were analyzed with Kaplan-Meier survival analysis. The results showed that N stage, M stage, and the density of IDO+cells in TDLN indicated a poor prognosis, whereas the T stage was not related to survival in this group of patients, which might derive from the obvious bias of T stage, with only one T1 and T4 patient studied. In contrast, as compared with non-cancer tissues, the increased expression of IDO was not observed in primary tumors. However, the decreased level of IDO was documented in lymph nodes metastases. These data suggest that the activity of IDO in tumor cells and immune cells differs.

Discussion

To determine the role of IDO activity in the progression of colon cancers, this study analyzed the expression of IDO in tumor cells from primary tumors and lymph node metastases, in normal epithelial cells from non-cancerous tissues, and in immune cells from the TDLN. The results showed that a higher density of IDO+cells in TDLN was associated with a lower 5-year survival rate, which was a prognostic marker independent of TNM stage, although the T stage was not related to survival in this group of patients. However, the decreased level of IDO was documented in lymph nodes metastases. These data suggest that the activity of IDO in tumor cells and immune cells differs.

Although the expression of IDO in TDLN has been observed in human tumors, the prognostic role of IDO in TDLN has only been documented in melanoma [24-27]. Among melanomas, the IDO+cells in TDLN appeared to be a population of plasmacytoid dendritic cell-like cells which blocked the initial response to tumor antigens, inhibited the ability of activated T cells to kill tumor cells, and enhanced the suppressive activity of T regulatory cells, resulting in local immunosuppression [38-42]. Except for melanoma, a highly immunogenic tumor, the prognostic effect of the density of IDO+cells in TDLN among other solid tumors, such as colorectal cancer, with modest immunogenicity is still elusive. This study revealed that the patients with a higher density of IDO+cells in TDLN had a lower 5-year survival rate (37.5%) than patients with a lower density of IDO+cells in TDLN (73.1%; Fig. 2).

Table 3: The expression of IDO in primary tumors and matched lymph node metastases (N = 41)

|                | IDO expression |       |       |       | P value |
|----------------|---------------|-------|-------|-------|---------|
|                | -             | +     | ++    | +++   |         |
| Primary tumor  | 18 (43.9)     | 15 (36.6) | 6 (14.6) | 2 (4.9) | 0.020   |
| Metastasis     | 27 (65.9)     | 14 (34.1) | 0     | 0     |         |

Considering the fact that IDO was also expressed in normal epithelium, the levels of IDO between primary...
tumors and its adjacent non-cancerous tissues were compared in this study. The results showed that no difference in IDO expression was observed. Secondly, as Bin1 could regulate the transcription of IDO, the Bin1 expression was also examined [49,50]. Again, no relationship between Bin1 expression and IDO expression was observed. Finally, neither IDO nor Bin1 in primary colon cancers was associated with the 5-year survival rate. Thus, these data suggested that it was less likely that the IDO activity in primary colon cancers contributed to tumor progression, which contrasted to the previous observation [13]. This discrepancy might derive from the research strategy as the IDO expression in the adjacent tissue might not been carefully evaluated in the previous study.

The expression of IDO in cancer cells is associated with a poor prognosis, as documented in multiple solid tumors. In this study, as the up-regulation of IDO was not

Table 4: The association between survival and TNM stages, and the levels of IDO and Bin1 in patients with colon cancers (N = 60)

| Factors                         | B    | SE   | Wald | df | Sig. | Exp(B) | 95%CI  |
|--------------------------------|------|------|------|----|------|--------|--------|
|                                |      |      |      |    |      |        | Lower  | upper |
| T stage                        | -.118| .389 | .091 | 1  | .763 | .889   | .415   | 1.906 |
| N stage                        | .825 | .258 | 10.220| 1  | .001 | 2.281  | 1.376  | 3.783 |
| M stage                        | 3.212| .579 | 30.821| 1  | .000 | 24.830 | 7.989  | 77.173|
| IDO expression in primary tumors| .598 | .638 | .878 | 1  | .349 | 1.818  | .521   | 6.345 |
| Bin1 expression in primary tumors| -.241| .378 | .405 | 1  | .525 | .786   | .375   | 1.650 |
| The density of IDO+cells in TDLN| 1.321| .524 | 6.362| 1  | .012 | 3.746  | 1.342  | 10.452|

Figure 2
The association of overall survival with the density of IDO+ cells in TDLN in colon cancers. The patients with a low density of IDO+cells in TDLN were strongly associated with a higher 5-year survival rate (73.1%) than the patients with a high density of IDO+cells (37.5%; Kaplan-Meier analysis, P < 0.05).
observed in primary cancers, it is impossible to judge whetherIDO activity is involved in tumor progression. Therefore, this study further compared the levels of IDO between primary tumors and matched lymph node metastases. Decreased expression of IDO was observed in lymph node metastases. Since lymph node involvement contributed to poor survival, decreased IDO in lymph node metastases do not support the hypothesis that IDO expressed by metastatic cancer cells contributes to metastasis by direct induction of local immunosuppression [51-55]. Therefore, these data suggest that IDO might have other potential than immunosuppression in metastatic colon cancer cells, although more evidence is needed to confirm this hypothesis. Based on the potential pluripotency of IDO, more specific IDO inhibitor might be needed for tumor therapy [56].

Conclusion
This study observed the paradoxical patterns of IDO expression in colon cancer. One was the fact that a higher density of IDO cells existed in TDLN, the other was the fact that the down-regulation of IDO occurred in metastatic colon cancer cells. This paradoxical phenomenon implied that IDO activity might contribute to the progression of colon cancer by multiple mechanisms including immunosuppression.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
WXJ, DY, ZX, PZZ, and WDS carried out the cases collection, GFY and PRQ carried out the immunohistochemical staining work and analysis, ZXS and LJ conceived the study, participated in its design and coordination, and helped draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This study was supported by the National Nature Science Foundation (30872931) and the Nature Science Foundation of Guangdong Province, China (05001693).

References
1. Munn DH, Mellor AL: Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007, 117(5):1147-1154.
2. Takikawa O: Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. Biochim Biophys Res Commun 2005, 338(1):12-19.
3. King NJ, Thomas SR: Molecules in focus: indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol 2007, 39(12):2167-2172.
4. Munn DH: Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 2006, 18(2):220-225.
5. Munn DH, Zhou M, Artwood J, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL: Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281(5380):1191-1193.
6. Mellor AL, Munn DH: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004, 4(10):762-774.
7. Alexander AM, Crawford M, Bertera S, Rudert WA, Takikawa O, Robbins PD, Trucco M: Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabeticogenic splenocytes. Diabetes 2002, 51(2):356-365.
8. Jalili RB, Rayat GR, Rajotte RV, Ghahary A: Suppression of islet allogeneic immune response by indoleamine 2,3-dioxygenase-expressing fibroblasts. J Cell Physiol 2007, 213(1):137-143.
9. Hayashi T, Beck L, Rossetto C, Gong X, Takikawa O, Takabayashi K, Broide DH, Carson DA, Raz E: Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest 2004, 114(2):270-279.
10. Wntenhave C, Plowte L, Theaste I, Stroobant V, Colau D,Parmentier N, Boon T, Eynde B, Van den E: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003, 9(10):1269-1274.
11. Zheng X, Koropatsch J, Li M, Zhang X, Ling F, Ren X, Hao X, Sun H, Vlassak G, Franke JA, Feng B, Urquhart BL, Zhong R, Freeman DJ, Garcia B, Min WP: Reinstalling autitumor immunity by inhibiting tumor-derived immuno-suppressive molecule IDO through RNA interference. J Immunol 2006, 177(8):5639-5646.
12. Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokoro K, Takahashi N, Terauchi M, Nakamura S, Nagasaka T, Takikawa O, Kikkawa F: Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 2006, 95(11):1555-1561.
13. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel H, Margreiter R, Konigsrainer A, Fuchs D, Amberger A: Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006, 12(4):144-151.
14. Chen PV, Mellon JK, Mayhew E, Wang S, He YG, Hogan N, Niederkorn JY: Uveal melanoma expression of indoleamine 2,3-dioxygenase: establishment of an immune privileged environment by tryptophan depletion. Exp Eye Res 2007, 85(5):617-625.
15. Sedlmayr P, Semlisch M, Gebru G, Karpf E, Reich O, Tang T, Wintersteiger R, Takikawa O, Dohr G: Expression of indoleamine 2,3-dioxygenase in carcinoma of human endometrium and uterine cervix. Adv Exp Med Biol 2003, 527:91-95.
16. Kanekas V, Zamanakou M, Kerenidis T, Dababreh I, Hevas A, Nakou M, Gourgoulianis KI, Gergatas AE: Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther 2007, 6(8):258-262.
17. Pan K, Wang W, Chen MS, Zhang HK, Weng DS, Zhou J, Huang W, Li JJ, Song HP, Xia JC: Expression and prognostic role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008, 134(11):1247-1253.
18. Riesenberg R, Weiler C, Spring O, Eder M, Buchner A, Castro M, Kammerer R, Takikawa O, Hatz RA, Stief CG, Hofstetter A, Zimmermann W: Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res 2007, 13(23):6993-7002.
19. Takao M, Okamoto A, Nikaido T, Ushimaru M, Takakura O, Saito M, Saito M, Okamoto S, Takikawa O, Sasaki H, Yasuda M, Ochiai K, Tanaka T: Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep 2007, 17(6):1331-1339.
20. Travers M, Gow IF, Barber MC, Thomson J, Shennan DB: Indoleamine 2,3-dioxygenase activity and L-tryptophan transport in human breast cancer cells. Biochim Biophys Acta 2004, 1661(1):106-12.
21. Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M, Nawa A, Nagasaka T, Takikawa O, Kikkawa F: Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 2008, 14(8):2310-2317.
22. Munn DH, Mellor AL: The tumor-draining lymph node as an immune-privileged site. Immunol Rev 2006, 213:146-158.
23. Terness P, Chuang JJ, Opelz G: The immunoregulatory role of IDO-producing human dendritic cells revisited. Trends Immunol 2006, 27:68-73.
24. Lob S, Konigrainer A: Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction? *Lancet Infect Dis* 2008, 8(6):995-1003.

25. Negin B, Pankia D, Wang W, Siddiqui M, Tawa N, Mullen J, Tahan S, Mandato L, Polivy A, Mier J, Atkins M: Effect of melanoma on immune function in the regional lymph node basin. *Clin Cancer Res* 2008, 14(3):654-659.

26. Yan MC, Lin CC, Chen YL, Huang SS, Yang HJ, Chang CP, Lei HY, Lai MD: A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. *Clin Cancer Res* 2009, 15:641-649.

27. Ou X, Cai S, Liu P, Zeng J, He Y, Wu X, Du J: Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrole 2,3-dioxygenase inhibitor, 1-MT. *J Cancer Res Clin Oncol* 2008, 134:525-533.

28. Miyazaki T, Moritake K, Yamada K, Hara N, Osago H, Shibata T, Akiyama Y, Tsuchiya M: Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. *J Neurosurg* 2009 in press.

29. Hou DY, Muller AJ, Shrivastava MD, DuHadaway J, Banerjee T, Johnson P, Mellor AL, Prendergast GC, Munn DH: Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antigen responses. *Cancer Res* 2007, 67(2):792-801.

30. Mackenzie T, Gralow J, Hepler K, Muller A, Daubener W: Role of indoleamine 2,3-dioxygenase in antimicrobial defence and immune regulation: tryptophan depletion versus production of toxic kynurenines. *Curr Drug Metab* 2007, 8(3):237-244.

31. Burke F, Knowles RG, East N, Balkwill FR: The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma. *Int J Cancer* 1995, 60(1):112-122.

32. Gasparri AM, Jachetti E, Colombo B, Sacchi A, Curnis F, Rizzardi GP, Traversari C, Bellone M, Corti A: Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNgamma. *Cancer Res* 2007, 7(12):3859-3866.

33. Melchior B, Hu W, Patena R, Melicharova K, Gallardo ST, Freedman R: rIFN-gamma-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition. *J Transl Med* 2003, 1(1):5.

34. Kananakis V, Speretas M, Zamanakou M, Kalata F, Loules G, Kerendi T, Barda AK, Gouqorgulian KI, Gerimens AE: Foxp3 expression in human colorectal cancer: relation to local regulatory T cells, 2,3-dioxygenase and indoleamine-2,3-dioxygenase inhibitor, 1-MT. *J Pathol Cancer* 2007, 117(9):2570-2582.

35. von Bergwalt-Baidon MS, Popov A, Saric T, Chemnitz J, Classen S, Stoffel MS, Fiore F, Roth U, Beyer M, Debey S, Wickenhauser C, Hanisch FG, Schultze JL: CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. *Blood* 2008, 108(1):228-237.

36. Muller DH, Sharma MD, Tou D, Dabu B, Lee JR, Antonia SJ, Miller ME: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. *Clin Cancer Res* 2004, 11(4):280-290.

37. Liang Y, Muller AJ, Munn DH, Prendergast GC, Munn DH: T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3-dioxygenase. *Handb Exp Pharmacol* 2009, 188:155-196.

38. Liu JY, Zhang XS, Ding Y, Peng RQ, Cheng X, Zhang NH, Xia JC, Zeng YX: The changes of CD4+CD25+CD4+ proportion in spleen of tumor-bearing BALB/c mice. *J Transl Med* 2005, 3(1):5.

39. Gajewski TF, Meng Y, Blank C, Brown J, Kline J, Harlin H: Immune resistance orchestrated by the tumor microenvironment. *Immunol Rev* 2006, 213:131-145.